HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hiroki Ishikawa Selected Research

asunaprevir

1/2019Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects.
11/2018Exposure-Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection.
11/2018Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection.
9/2018Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
9/2017Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions.
3/2017Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.
1/2016Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients.
7/2015High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms.
6/2014Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.
4/2013Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hiroki Ishikawa Research Topics

Disease

20Infections
03/2020 - 06/2004
18Hepatocellular Carcinoma (Hepatoma)
03/2020 - 04/2002
10Neoplasms (Cancer)
03/2020 - 05/2002
10Fibrosis (Cirrhosis)
01/2019 - 06/2003
6Chronic Hepatitis B
05/2011 - 06/2009
5Chronic Hepatitis C
11/2018 - 03/2012
4Virus Diseases (Viral Diseases)
11/2018 - 10/2011
4Headache (Headaches)
06/2014 - 03/2012
4Bites and Stings (Sting)
10/2011 - 10/2008
3Inflammation (Inflammations)
12/2021 - 06/2003
3Body Weight (Weight, Body)
01/2019 - 04/2012
3Hepatitis C
09/2017 - 05/2002
3Diarrhea
06/2014 - 03/2012
3Type 1 Diabetes Mellitus (Autoimmune Diabetes)
11/2008 - 06/2006
2Fatty Liver
03/2018 - 01/2003
2Bacterial Infections (Bacterial Infection)
12/2016 - 08/2012
2Fever (Fevers)
06/2014 - 01/2014
2Nasopharyngitis
06/2014 - 04/2013
2Asthma (Bronchial Asthma)
04/2012 - 08/2004
2Autoimmune Diseases (Autoimmune Disease)
11/2008 - 06/2006
1Synovitis
05/2022
1Rheumatoid Arthritis
05/2022
1Gram-Positive Bacterial Infections
12/2021
1Hyperammonemia
08/2021
1Measles
09/2019
1Insulin Resistance
03/2018
1Chronic Disease (Chronic Diseases)
03/2018
1Viremia
09/2017
1Poisoning
07/2016
1Colitis
05/2016
1Anemia
01/2016
1Exanthema (Rash)
01/2016
1Alopecia (Baldness)
01/2014
1Opportunistic Infections (Opportunistic Infection)
11/2013
1Caliciviridae Infections
05/2013

Drug/Important Bio-Agent (IBA)

16InterferonsIBA
09/2018 - 06/2002
13daclatasvirIBA
11/2018 - 03/2012
12asunaprevirIBA
01/2019 - 03/2012
7CytokinesIBA
05/2022 - 06/2002
7Ribavirin (Virazole)FDA LinkGeneric
01/2016 - 03/2012
6Antiviral Agents (Antivirals)IBA
11/2018 - 06/2002
6RNA (Ribonucleic Acid)IBA
09/2018 - 05/2003
6entecavirFDA Link
05/2011 - 06/2009
6DNA (Deoxyribonucleic Acid)IBA
04/2011 - 05/2003
5Alanine Transaminase (SGPT)IBA
01/2019 - 06/2003
4NF-kappa B (NF-kB)IBA
12/2021 - 03/2003
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
05/2022 - 03/2003
3VaccinesIBA
09/2019 - 05/2005
3Aspartate Aminotransferases (Aspartate Transaminase)IBA
11/2018 - 06/2014
3alpha-Fetoproteins (alpha-Fetoprotein)IBA
09/2018 - 04/2002
3Protease Inhibitors (Protease Inhibitor)IBA
07/2015 - 04/2013
3Proteins (Proteins, Gene)FDA Link
11/2013 - 06/2003
3Lamivudine (Epivir)FDA Link
07/2010 - 09/2009
3NucleosidesIBA
06/2010 - 06/2009
3Monoclonal AntibodiesIBA
11/2008 - 06/2006
2lenvatinibIBA
03/2020 - 09/2019
2EnzymesIBA
09/2019 - 07/2004
2Immunoglobulin G (IgG)IBA
09/2019 - 08/2004
2CholesterolIBA
01/2019 - 03/2018
28- cyclohexyl- N- ((dimethylamino)sulfonyl)- 1,1a,2,12b- tetrahydro- 11- methoxy- 1a- ((3- methyl- 3,8- diazabicyclo(3.2.1)oct- 8- yl)carbonyl)cycloprop(d)indolo(2,1- a)(2)benzazepine- 5- carboxamideIBA
09/2018 - 03/2017
2Messenger RNA (mRNA)IBA
05/2016 - 05/2013
2telaprevirIBA
01/2016 - 12/2015
2Pharmaceutical PreparationsIBA
01/2016 - 04/2004
2Transaminases (Aminotransferases)IBA
04/2013 - 03/2012
2AntigensIBA
04/2012 - 01/2004
2B-Form DNA (B-DNA)IBA
10/2009 - 10/2008
2Interferon-alpha (Interferon Alfa)IBA
10/2003 - 03/2003
1Prostaglandin-E SynthasesIBA
05/2022
1InterleukinsIBA
05/2022
1Cyclooxygenase 2 (Cyclooxygenase-2)IBA
05/2022
1Matrix Metalloproteinases (MMPs)IBA
05/2022
1Protein Phosphatase 2 (Protein Phosphatase 2A)IBA
12/2021
1Cyclic GMP-Dependent Protein Kinases (Protein Kinase G)IBA
12/2021
1Secretory Immunoglobulin A (SIgA)IBA
03/2020
1Interleukin-4 (Interleukin 4)IBA
03/2020
1Triglycerides (Triacylglycerol)IBA
01/2019
1Glucose (Dextrose)FDA LinkGeneric
01/2019
1LDL CholesterolIBA
01/2019
1oxidized low density lipoproteinIBA
01/2019
1TabletsIBA
11/2018
1Capsules (Microcapsules)IBA
11/2018
1LipidsIBA
03/2018
1Placental ExtractsIBA
03/2018
1Nicardipine (Dagan)FDA LinkGeneric
09/2017
1Granulocyte Colony-Stimulating Factor (G-CSF)IBA
12/2016
1HydrogenIBA
07/2016
1IonsIBA
07/2016
1Dextran SulfateIBA
05/2016
1Immunoglobulin E (IgE)IBA
05/2016
1Interleukin-12 (IL 12)IBA
01/2016
1SimeprevirIBA
12/2015
1peginterferon alfa-2b (Pegintron)FDA Link
01/2014
1peginterferon alfa-2a (Pegasys)FDA Link
01/2014
1LactoferrinIBA
05/2013

Therapy/Procedure

10Therapeutics
07/2015 - 01/2004
2Immunotherapy
11/2008 - 06/2006
2Oral Administration
11/2008 - 08/2007
2Transplantation
11/2008 - 06/2006
1Aftercare (After-Treatment)
08/2021
1Intranasal Administration
01/2016